Mounting evidences show that EZH2 is upregulated in multiple malignancies, such as osteosarcoma, breast cancer, melanoma, prostate cancer, and OvCa, and its overexpression is related to the metastatic ability of some aggressive tumors 33-38. This evidence concerns the gene EZH2 and prostate cancer.